News | October 30, 2024
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Strong topline growth driven by solid performance across key brands.
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
New Board of Directors and management team at Suven Pharma also appointed
Subscribe To Our Newsletter & Stay Updated
